Text Size
Trial record 8 of 200 for:    sinusitis
Previous Study | Return to List | Next Study

Efficacy of Azithromycin Prophylaxis in Preventing Recurrent Acute Sinusitis in Children

This study is currently recruiting participants.
Verified February 2013 by Mahidol University
Sponsor:
Information provided by (Responsible Party):
Orathai Piboonpocanun, Mahidol University
ClinicalTrials.gov Identifier:
NCT00944515
First received: July 22, 2009
Last updated: February 18, 2013
Last verified: February 2013
History of Changes
  Purpose

The purpose of this study is to evaluate efficacy of azithromycin prophylaxis in preventing recurrent acute sinusitis in children.


Condition Intervention
Sinusitis
 Drug: placebo
Drug: azithromycin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Efficacy of Azithromycin Prophylaxis in Preventing Recurrent Acute Sinusitis in Children : A Prospective, Randomized, Double-blind, Placebo Controlled Trial.

Resource links provided by NLM:

MedlinePlus related topics: Sinusitis
U.S. FDA Resources

Further study details as provided by Mahidol University:

Primary Outcome Measures:
  • frequence of acute sinusitis during 12 mouths of study period [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 40
Study Start Date: August 2009
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: azithromycin
azithrimycin 3 days/week
 Drug: azithromycin
azithromycin 3 days/week
Other Name: treatment
Placebo Comparator: placebo
placebo 3 days/week
 Drug: placebo
placebo tablet or syrup 3 days/week
Other Name: placebo

Detailed Description:

A Prospective, Randomized, Double-blind, Placebo Controlled Trial of azithromycin in preventing recurrent acute sinusitis in children

  Eligibility

Ages Eligible for Study:   5 Years to 15 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • children between the age of 5 years and 15 years with the diagnosis of recurrent acute sinusitis who are attending the outpatient pediatric department, pediatric allergy clinic, and the ear, nose, throat clinic.

Exclusion Criteria:

  • patients who have allergic rhinitis, chronic sinusitis, a history of allergic reactions to azithromycin or macrolides, treatments with immunotherapy or IVIG or gentamycin solution or pneumococcal vaccine during study period.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00944515

Contacts
Contact: Orathai Piboonpocanun 662-419-8888 ext 5942 jirapongo@yahoo.com

Locations
Thailand
Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University Recruiting
Bangkok, Thailand, 10700
Contact: Orathai Piboonpocanun, Assoc.Prof.     662-419-7000 ext 5942     jirapongo@yahoo.com    
Principal Investigator: Orathai Piboonpocanun, Assoc.Prof.            
Sponsors and Collaborators
Mahidol University
Investigators
Principal Investigator: Orathai - Piboonpocanun, MD Siriraj Hospital, Mahidol University
  More Information

No publications provided

Responsible Party: Orathai Piboonpocanun, Department of Pediatrics, Faculty of medicine, Siriraj hospital, Mahidol University
ClinicalTrials.gov Identifier: NCT00944515     History of Changes
Other Study ID Numbers: 394/2551(EC4)
Study First Received: July 22, 2009
Last Updated: February 18, 2013
Health Authority: Thailand: Ethical Committee

Keywords provided by Mahidol University:
sinusitis
azithromycin

Additional relevant MeSH terms:
Sinusitis
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
 Azithromycin
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 17, 2013